Horizon is a leading life science company supplying research tools to organizations engaged in genomics research and the development of personalized medicines. The Company combines revenue generating products and services with an ability to leverage its IP platform and know-how into its customer’s value chain, yielding significant upside potential. Horizon, which is Cambridge (UK) based, has a diverse and international customer base approaching 800 organizations, including major pharmaceutical, biotech and diagnostic companies as well as leading academic research centres. The Company supplies its products and services into multiple markets, estimated to total in excess of £29 billion by 2015, including the translational genomics research market; the cell based assays market; the molecular diagnostics market, and the biopharmaceutical production market.
Horizon has raised approximately £20m since its Seed investment in March 2008 and investors include: MVM Life Sciences LLP, DFJ Esprit LLP, Roche Venture Fund, Dr Jonathan Milner, Mr David Evans, Mr Peter Collins, Providence Investment Company Ltd and Mr David Cleevely.
For further information please contact:
Consilium Strategic Communications
Amber Bielecka / Mary-Jane Elliott / Jessica Hodgson / Matthew Neal
Telephone: +44 (0) 207 920 2352